25 - HIV State of the ART

Thursday, October 20, 2022

10:30 AM – 11:45 AM US ET

Location: Ballroom ABC (3rd Floor)

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Harry Lampiris, MD

Chief, Infectious Disease Section, Medical Service
San Francisco VA Medical Center/UCSF
San Francisco, CA, United States

Disclosure(s): No financial relationships to disclose
Matthew Spinelli, MD, MAS

Assistant Professor
University of California, San Francisco
San Francisco, CA, United States

Disclosure(s): No financial relationships to disclose

Faculty(s)

Charles Flexner, MD (he/him/his)

Professor
Johns Hopkins School of Medicine
Baltimore, MD, United States

Disclosure(s): Gilead Sciences: Advisor/Consultant (Ongoing); Janssen Pharmaceutical Company of J&J: Advisor/Consultant (Terminated); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Navigen: Board Member (Ongoing); Viiv Healthcare: Advisor/Consultant (Ongoing)

Slides
Dan Barouch, MD, PhD

Director-Center for Virology and Vaccine Research
Harvard Medical School
Boston, MA, United States

Disclosure(s): Gilead: Grant/Research Support (Ongoing); Janssen Pharmaceutical Company of J&J: Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing); Sanofi Pasteur Inc.: Grant/Research Support (Ongoing)

Slides
Marina Caskey, MD

Professor
Rockefeller University
New York, NY, United States

Disclosure(s): Abbvie: Advisor/Consultant (Terminated); Gilead Biosciences: Advisor/Consultant (Ongoing)

Disclosure(s):

Harry Lampiris, MD: No financial relationships to disclose

Matthew A. Spinelli, MD, MAS: No financial relationships to disclose

Charles W. Flexner, MD: Gilead Sciences: Advisor/Consultant (Ongoing); Janssen Pharmaceutical Company of J&J: Advisor/Consultant (Terminated); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Navigen: Board Member (Ongoing); Viiv Healthcare: Advisor/Consultant (Ongoing)

Dan Barouch, MD, PhD: Gilead: Grant/Research Support (Ongoing); Janssen Pharmaceutical Company of J&J: Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing); Sanofi Pasteur Inc.: Grant/Research Support (Ongoing)

Marina Caskey, MD: Abbvie: Advisor/Consultant (Terminated); Gilead Biosciences: Advisor/Consultant (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify new strategies for HIV cure;
describe new approaches to HIV treatment;
identify new biomedical approaches to HIV prevention

Presentations:

10:30 AM – 10:55 AM US ET

Long-Acting Antiretroviral Therapy for Treatment of HIV
Speaker: Charles W. Flexner, MD (he/him/his) – Johns Hopkins School of Medicine
10:55 AM – 11:20 AM US ET

Vaccine Strategies for HIV-1 Infection
Speaker: Dan Barouch, MD, PhD – Harvard Medical School
11:20 AM – 11:45 AM US ET

HIV Cure Strategies
Speaker: Marina Caskey, MD – Rockefeller University